source
- Degron Therapeutics raises $40M in Series A extension, total $95M, as Cabaletta releases early CAR‑T dataDegron Therapeutics, a US‑China biotech focused on molecular‑glue degrader technology, announced an additional $40 million in Series A extension funding, bringing its total capital raised to $95 mi…
- Biogen reports mixed results in mid‑stage trial of tau‑targeting Alzheimer’s therapyBiogen disclosed data from a Phase 2 study of its experimental Alzheimer’s drug that targets the tau protein. The trial showed a combination of positive and negative signals, with some measures ind…